中晚期宫颈癌动脉新辅助化疗的临床分析
摘要
目的:探讨宫颈癌新辅助化疗方法,在中、晚期患者治疗中的临床疗效和意义。方法:回顾性分析我院就诊治疗的67例Ib-IIIb期宫颈癌患者,分析IIb-IIIb期患者行经皮股动脉双侧髂内动脉灌注疗法的近期临床疗效、手术率、影响因素及副作用;与同期Ib-IIa期手术患者对比,评价晚期患者化疗后进行广泛子宫切除+盆腔淋巴结清扫术的可行性。结果:所有化疗患者临床症状均得到缓解,化疗总体有效率77%,手术率46.7%,II、III期患者临床有效率无明显差异,(P>0.05),临床分期、组织学分化与化疗缓解率之间无明显关系,(P>0.05);化疗后多数患者出现轻度骨髓抑制及肝、肾功能损害,(P<0.05),无临床不能耐受的毒副反应;化疗患者根治术后保留尿管时间略长,(P<0.05),手术时间、术中出血量及淋巴转移率与对照组相比无明显差异,(P>0.05)。结论:新辅助化疗治疗对中晚期宫颈癌患者有较好的近期疗效及手术率,且不增加经腹广泛子宫切除术及盆腔淋巴结清扫术的术中困难程度及术后并发症,是一种有效的综合治疗方法。对远期疗效及生存率的影响,仍需大量临床病例及长期随访的验证。
Objective: To investigate the curative effect and clinical meaning of scheme intra-arterial neoadjuvant chemotherapy treated patients with metaphase or advanced cervical carcinoma. Methods: A retrospective analysis of 67 patiens within cervical carcinoma stage Ib-IIIb in our hospital. To analyze the short-term clinical curative effect, operation rate, influencing factor and side effect after the Intra-arterial neoadjuvant chemotherapy for the patients with stage IIb-IIIb; to evaluate the feasibility to have the operation with radical hysterectomy and pelvic lymphadenetomy for patients with metaphase or advanced cervical carcinoma after chemotherapy contrasted with Ib-IIa patients. Results: To a certain degree ,clinical symptom of patients had relieved, overall remission rate 77%, and the operation rate is 46.7%,there was no significant difference in the short-termeffect rate ,clinical stage and histology with chemo remission rate between the two groups in stage II and III, (P>0.05). After the neoadjuvant chemotherapy the most patients had light bone marrow depression, liver function and renal function lesion, and didnot exist severe side reaction. (P<0.05), After the operation ,the chemotherapy patient had more time retained the ureter than other, (P<0.05). It is no obvious difference in operation time, operation bleeds and lymph transfer rate compared with the other group,(P>0.05). Conclusion: The Intra-arterial neoadjuvant chemotherapy had better recent curative effect and operation rate for patients with metaphase or advanced cervical carcinoma. It does not increase postoperative complications and the difficult degree of radical hysterectomy and pelvic lymphadenetomy. It is a kind of effective comprehensive therapy. But,its influence for long-term curative effect and survival rate still need a large number of clinical cases and a long time following up to verify.
Objective: To investigate the curative effect and clinical meaning of scheme intra-arterial neoadjuvant chemotherapy treated patients with metaphase or advanced cervical carcinoma. Methods: A retrospective analysis of 67 patiens within cervical carcinoma stage Ib-IIIb in our hospital. To analyze the short-term clinical curative effect, operation rate, influencing factor and side effect after the Intra-arterial neoadjuvant chemotherapy for the patients with stage IIb-IIIb; to evaluate the feasibility to have the operation with radical hysterectomy and pelvic lymphadenetomy for patients with metaphase or advanced cervical carcinoma after chemotherapy contrasted with Ib-IIa patients. Results: To a certain degree ,clinical symptom of patients had relieved, overall remission rate 77%, and the operation rate is 46.7%,there was no significant difference in the short-termeffect rate ,clinical stage and histology with chemo remission rate between the two groups in stage II and III, (P>0.05). After the neoadjuvant chemotherapy the most patients had light bone marrow depression, liver function and renal function lesion, and didnot exist severe side reaction. (P<0.05), After the operation ,the chemotherapy patient had more time retained the ureter than other, (P<0.05). It is no obvious difference in operation time, operation bleeds and lymph transfer rate compared with the other group,(P>0.05). Conclusion: The Intra-arterial neoadjuvant chemotherapy had better recent curative effect and operation rate for patients with metaphase or advanced cervical carcinoma. It does not increase postoperative complications and the difficult degree of radical hysterectomy and pelvic lymphadenetomy. It is a kind of effective comprehensive therapy. But,its influence for long-term curative effect and survival rate still need a large number of clinical cases and a long time following up to verify.
引文
[1] Parkin DM,Bray F,Ferlay J,et al.Estimating the world cancer burden, globocan 2000 Int J cancer,2001,(94):153-156.
[2] Rose PG.Locally advanced cervical cancer.Curr Opin Obstet Gynecol,2001,(l):65-70.
[3] Scarabelli C,Zarrelli A,Gallo A,et al.Multimodal treatment with neoadjuvant intra-arterial chemotherapy and radical surgery in Patients with IIIb-IVa cervical cancer.A Preliminary study,Cancer,1995,(76):1019-1026.
[4] Park SY, Kim JH, Lee JH. Phase I-II study of neoadjuvant intra-arterial chemotherapy with mitomycin-C,vincristine and cisplatine in patients with stage IIb bulky cercical carcinoma.Cancer,1995,(76):814-823.
[5] Leone B,Vallejo C, Perez J,et al.Ifosfamide and cisplatine as neoadjuvant themotherapy for advanced cervical carcinoma. Am J Clin Oncol,1996,(19):132-135.
[6]赖日权,张小庄.宫颈/阴道组织与细胞病理学诊断.第1版,北京科学出版社,2004,3-5.
[7]周际昌.实用肿瘤内科学.北京人民卫生出版社,1999,33-342.
[8]王玲.宫颈癌病因学研究新近展.中国妇产科临床杂志,2003,4:243.
[9]李庭芳,古丽娜.库尔班,王涛,等.新疆伽师县夏普桃勒乡妇女子宫颈癌防治的研究.新疆医学院学报,1996,19(3)199-203.
[10]拉莱.苏祖克,古丽娜.库尔班,Amy E.Noeffsrniger,等.维吾尔妇女子宫颈癌中p53基因的表达和HPvDNA检测研究.新疆医学院学报,1997,20(2):77-81.
[11]马正海,钱东,马纪,等.中国新疆维吾尔族妇女宫颈癌组织中乳头状瘤病毒16型E6基因的克隆和序列分析生物化学与生物物理进展,2001,28(3):400-404.
[12]古扎丽努尔.阿不力孜,彭芝兰,刘姗玲,等.新疆和田地区维吾尔族妇女宫颈癌组织中HPvDNA的测定[JJ].四川肿瘤防治,2001,14(2):77-81.
[13]古丽娜.库尔班,阿依努尔.买买提,古扎丽努尔.阿不力孜,等.人类乳头瘤病毒及其亚型在新疆南部地区维族妇女宫颈癌组织中的分布.肿瘤,2002,14(2)405-408.
[14]刘萍,陈春林,梁立治,等.介入性化疗在宫颈癌手术前的应用.中国实用妇科与产科杂志,2001,17(11):666-668.
[15]章华文,吴令英.关于子宫颈癌综合治疗的商榷.中华肿瘤志,2003,25:206-208.
[16] Benedetti-Panici P,Greggi S,Colombo A,et al.Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer results from the Italian multicenter randomized study[J].J Clin Oncol,2002,20(1):179-188.
[17] Maneo A,Colombo A,Landoni F,et al.Treatment of stage IIIB cervical carcinoma a comparison between radiotherapy,concur-rent chemo-radiotherapy and neoadjuvant chemotherapy[J].Mi-nerva G inecol,2005, 57(2):141-152.
[18] Fattorossi A,Battaglia A,Ferrandina G,et al.Neoadjuvant therapy changes the lymphocyte composition of tumor-draining lymph nodes in cervical carcinoma[J].Cancer,2004,100(7):1418.
[19] Antonella Savarese,Franeeseo Cognetti.New drugs in the treatment of recurrent or metastatic cervical cancer. Critical Reviews on Oncology / hematology ,2003,48(30):323-327.
[20] Kobayashi K,Furukawa A,Takahashi M,et al.Neoadjuvant intra-Arterial chemotherapy for locally advanced uterine cervical cancer: Clinical efficacy and Factors Influencing response. Cardiovasc Intervent Radiol,2003,26(2):20-25.
[21]贺青蓉.介入治疗30例中、晚期宫颈癌疗效观察.临床放射学杂志,2002,18(11): 995-996.
[22] Park DC,Kim JH,Lew YO,Kim DH,et tl.Phase II trial of neoadjuvant paclitaxel and cisplatin in uterine cervical cancer[J].Gynecol oncol.2004 ,92(1):59-63.
[23] Mutch DG,Bloss JD.Gemeitabine in cervical cancer[J].Gynecol Oneol,2003,90(2):8-15.
[24] Va11ejo CT,Machiavelli MR,Perez JE,RomeroAO,et al.Docetaxel as neoadjuvant chemotherapy in Patients with advaneed cervical eareinoma[J].Am J Clin oncol.2003,26(5):477-482.
[25]陈春林,刘佩鸣,孙明晖,等.不同途径盆腔动脉灌注化疗组织血浆中铂浓度的研究.中国实用妇科与产科杂志, 1998, 14:357-358.
[26] Stewand PSL, Stenven MA. Clinical pharmacology of intraarterial cisddiam minedich coroplatinum (Ⅱ).Center Reseach,1983,43:97-106.
[27]孙秀丽,王建六,屠铮,等.子宫内膜癌术中区域性动脉灌注化疗的治疗观察.中国妇产科临床杂志, 2003, 4:165-167.
[28] Reuter H.Interventional therapy timing crucial in cervical cancer[J].Eur Cancer,2003,39:2470.
[29] Usuki N,Hitokawa K,Tashiro T,et al. Intra-arterial chemotherapy for uterine cervical adenoarcinoma evaluation of its efficacy as therapy. Nippo Jgaku Hoshasen Gakkai Zasshi,1999,59(12):670-673.
[30] Nagata Y,Araki N,Kimura H,et al.Neoadjuvant chemotherapy by transcatheter arterial infusion method for uterine cervical cancer.J Uasc Interv Radiol,2000,11(3):313.
[31] Brader KR,Motris M,Levenbaek C,et al.Chemotherapy for cervical carcinoma:factors determining response and implications for clinical trial desigin. J Clin oncol,1998,6(5):1879-1884.
[32] Kobeyashi K,Furukawa A,Takahashi M,et al.Neoadjuvant intra-arterial chemotherapy for locally advanced uterine cervical cancer:Clinical efficacy and factors influencing response. Cardiovase Intervent Radiol,2003,26(2):20-25.
[33] Fujiwaki R,Maede Y,Ohnishi Y,et al.Prognosis of patienis with stage IIIb-IVa squamous cell carcinoma of the cervix following intra-artirial neoadjuvant chemotherapy. J ExP Clin Cancer Res,1999,18(2):143-146.
[34] Minagaway Y,Kigawa J,Irie T,e tal.Radical surgery following neoadjuvant chemotherapy for patients with stage IIIb cervical cancer.Ann Surg Oncol,1998,5(6):539-543.
[35] Benedetti-Paniei P,Greggi S,Colombo A,et al.Neoadjuvant chemotheraphy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer:results from the Ita1ian mu1tieenter randomized study.J Clin Oncol,2002,20(1):179-183.
[36]吕雯,麻亚茜,隋丽华.新辅助化疗对宫颈微血管密度及血管内皮生长因子的影响.现代妇产科进展,2004,13:28-30.
[37] Kobayashi K,Furukawa A,Takahashi M,et al.Neoadjuvant intra-arterial chemotherapy for locally advanced uterine cervical cancer: clinical efficacy and factors influencing response,Cardiovasc Intervent Radiol,2003,26(3):234-241.
[38] Vagno G,Cormio G,Pignata S,et al.Cisplatin and vinorelbine as neoadjuvant chemotherapy in locally advanced cervical cancer:aphase II study.Int J Gynecol Cancer,2003,13(3):308-312.
[39] Yamakawa Y,Fujimura M,Hidaka T,et al.Neoadjuvant intrarterial infusion chemotherapy in patients with stage IB2-IIIB cervical cancer.Gynecol Oncol,2000,77(2):264-270.
[40] Nagata Y,Araki N,Kimura H,et al.Neoadjuvant chemotherapy by transeatheter terial infusion method for uterine cervical cancer:J Vase Int Radiol,2000,11(3):313-319.
[41] Lopez-Graniel C,Reys M,Chanona G,et al.Type III radical hysterectomy after Induction chemotherapy for patients with locally advanced cervical carcinoma[J].Int J Gynecol cancer,2001,1(3):210-217.
[42] Sardi JE,Boixadera MA,Sardi JJ.Neoadjuvant chemotherapy in cervical cancer:a new trend.Curr Opin Obstet Gynecol,2005,17(1):43-47.
[43] Panetta A,Angelelli B,Martoni A.Pilot study on induction chemotherapy with cisplatin,epirubicin,etoposide and bleomycin in cervieal stage Ib,IIa and IIb.Anti cancer Res,1999,19(IB):765-768.
[44]吕雯,麻亚茜,隋丽华.新辅助化疗对宫颈微血管密度及血管内皮生长因子的影响.现代妇产科进展,2004,13:28-30.
[45] Fujiki R,Iida K,Ohnishi Y,et al.Intra-arterial neoadjuvant chemotherapy followed by radical surgery and radio therapy for stage IIb cervical carcinoma.Anti cancer Res,1997,17(SB):3751-3755.
[46] Seambja G,Ferrandina G,Distefano M,etal.Is there a place for a less extensive radical surgery in locally advanced cervical cancer patients Gynecol Oncol,2001,83:319-324.
[47]常丽锦.子宫颈癌的新辅助治疗.现代妇产科进展,2003,12(2):135.
[48]丁丽珠,李诚信.Ib-Hb期宫颈癌术前辅助化疗、放疗的疗效分析[J].中国癌症杂志,2004,14(6):558-562.
[49]段萍,孙敏.术前化放疗治疗11期宫颈癌疗效观察[J].浙江肿瘤,2000,6(4):208-210.
[50] Nagata Y, Okajima K, Konishil, et al. Clinical results of trans-catheterarterial infusion for uterine cervical cancer. Am J C1in Oncol,1999,22(1):97-102.
[51] Sugiyama T, Nishide T, Hasuo Y, et al. Neoadjuvant intra-arterial chemotherapy Followed by radical hysterectomy and/or radiotherapy for locally advanced cervical cancer. Gynecol Oncol,1998,69(2):130-136.
[52] Minagawa Y, kgawa J, Irie T, et al.Radical surgery following neoadjuvant chemotherapy for patienis with stage IIIB cervical cancer. Ann Surg Oncol,1998,5(6):539-543.
[53]陈春林,谭道彩,梁立治,等.动静脉灌注化疗子宫颈癌组织药物浓度的比较.中华妇产科杂志,1995,30(5):298.
[54] Adachi S, OAdachi S, Ogasawara T,et al. Intravenous nedaplatin and intraarterial cisplatin with transcatheter arterial embolization for patients with locally advanced uterine cervical cancer.Int J Clin Pharmacol Res,2001,21(3-4):105-106.
[55] Itamochi H, Kigawa J, Minagawa Y, et al. Antitum or effects of internal iliac arterial infusion of platinum compounds in a rabbit cervical cancer model,Obstet gynecol,1997,89:286.
[56]贾丽辰,王昭梅,黄淑馨,等.介入放射学在妇科恶性肿瘤中的应用.上海医学,1991,11(11):675.
[57] YamakawaY,FujimuraM,Hidaka T,et al.Neoadjuvantintraaterial infusion chemotherapy in patients with stage IB2-IIIBcervical cancer.GynecoOncol,2000,77(4):264-270.
[58] Onishi H,Yamaguchi M,Kuriyama K,et al.Effect of concurrent intraarterial infusion of platinum drugs for patients with stage III or IV uterine cervical cancer treated with radical radiation therapy.[J].Cancer J Sci Am,2000,6(1):40-45.
[59] Yamakawa Y, Fujimura M, Hidaka T,et al.Neoadjuvant in-traavterial infusion chemotherapy in patients with stage Ib2-IIIb cervix cancer[J].Gynecologic Oncology,2000,77:264-270.
[1]龚沂,蔡丽萍.宫颈癌的新辅助化疗.江西医学院学报,2004,44(5):43-44.
[2] Sardi J E,Boixadera M A,Sardi J J.Neoadjuvant chemotherapy incervical cancer:a new trend[J].Curr Opin Obstet Gynecol,2005,17(1):43-47.
[3]赵文娟.新辅助化疗在宫颈癌术前治疗中的应用[J]职业与健康,2007,23(9): 761-762.
[4]马秋英.宫颈癌手术前治疗[J].华夏医学,2007,20(5):1145-1148.
[5]王绍光.妇科恶性肿瘤动脉化疗的种类、途径和方式,实用妇产科杂志,2006,8[22]55-60.
[6] Kobayashi M,Yamamoto H, SugimotoT,et al.Intraoperative local infu-sion chemotherapy (ILIC) For gastric cancer.Gan-To-Kagaku-Ryo-ho,1998,25:1281- 1286.
[7]陈春林,刘佩鸣,孙明晖,等.不同途径盆腔动脉灌注化疗组织血浆中铂浓度的研究,中国实用妇科与产科杂志,1998,14:357-358.
[8] Stewand PSL,Stenven MA.Clinical pharmacology of intraarterial cisddi-am minedich coroplatinum (II) Center Reseach,1983,43:97-106.
[9]孙秀丽,王建六,屠铮,等.子宫内膜癌术中区域性动脉灌注化疗的治疗观察.中国妇产科临床杂志,2003,4:165-167.
[10]张国楠,宋水勤.宫颈癌动脉化疗进展.实用妇产科杂志,2006,8(22)70-72.
[11] Tabata T,Takeshima N,NishidaH,et al.Arandomized study ofprimary bleomycin, vincristine,mitomycinandcisplat(BOMP)chemotherapy followed by radiotherapy versus radiotherapy alone instage IIIB and IVA squamous cell carcinoma of the cervix[J].An-ticancer Res,2003,23:2885-2890.
[12]翟建军,战媛,闻静,等.局部晚期子宫颈癌应用新辅助化疗的探讨[J].中国医刊,2007,42(10):56-58.
[13] Adachi S,Ogasawara T,Tsubamoto H,et al.Intravenous nedapl-atin and intraarterial cisplatin with transcatheter arterial emboliza-tion for patientswith locally advanced uterine cervical cancer[J].Int JClin PharmacolRes,2001,21(3~4):105-110.
[14] Abu-Surrah AS,Kettunen M.Platinum group antitumor chemistry:design and development of newanticancer drugs complementary to cisplatin[J].Curr Med Chem,2006,13(11):1337-1357.
[15]于海林,鹿欣.铂类抗癌药物在妇科肿瘤治疗中的应用.世界临床药物医药专论,world clinical drugs, 2008[29]:7.
[16]刘飞,郭美君,苏日娜.宫颈癌的同步放化疗与新辅助化疗的研究进展.A cta A cadMed Nei Mongol, 2006,12:28.
[17]苗华芹,周登光,周登峰.高危宫颈癌化疗进展,实用癌症杂志,2005,5(20)3-5.
[18]刘颖,熊正爱.宫颈癌化学药物治疗进展.重庆医学学报,第2008,6(37)12-14.
[19] Serur E,Mathews RP,Gates J,et al.Neoadjuvant chemotherapy in stage IB2 squamous cell carcinoma of the cervix[J]Gynecol Oncol,1997,65(2):348.
[20] Neoadjuvant Chemotherapy for Cervical Cancer Meta-analysis Collaboration(NACCCMA)Collaboration Neoad-juvant chemotherapy for locally advanced cervix cancer[M/CD].Cochrane Database Syst Rev,2004,(2): 1774.
[21] Minagawa Y,Kigawa J,Irie T,et al.radical surgery following neoadjuvant chemotherapy for patients with stageIIIB cervical cancer[J].Ann Surg Oncol,1998,5(6):539.
[22] Chauvergne J,Lhomme C,Rohart J et al.Neoadjuvant chemoth-erapy of stage IIb or IIIcancers of the uterine cervix.Long-termresults of a multicenter randomized trial of 151 patients[J].Bull Cancer,1993,80(12):1069.
[23] Seoud M,Geara FB,Shamseddine A,et al.Short duration neoad-juvant chemotherapy followed by radiotherapy for advanced car-cinoma of the cervix:results and prognostic variables[J].Eur J Gynaecol Oncol,2003,24(2):163.
[24] Yamakawa Y,Fujimura M,Hidaka T,et al.Neoadjuvant intraar-terial infusion chemotherapy in patients with stageⅠB2~ⅢB cervical cancer[J].Gynecol Oncol,2000,77(2):264.
[25] Focan C,Denis B,Kreutz F,et al.Ambulatory chronotherwith 5-fluo-rouracil,folinic acid,and carboplatin for advanced non-small cell lung cancer.A phase II feasibility trial[J].J Infus Chemother,1995,5(3suppl):148~152.
[26]宋红林,宫颈癌的新辅助时辰化疗,Modern oncology,2003,8(11)3 186.
[27] CW,Park HJ,Lee CK,et al.Implications of increased tumor blood flow and oxygenation caused by mild temperature hyperther-mia in tumor treatment[J].Int J Hyperthermia,2005,21(8):761-770.
[28] Matrai Z,Peley G,Kovacs T,et al.Cytoreductive surgery and in-traperitoneal hyperthermic chemoperfusion for peritoneal carcino-matosis caused by recurrent inflammatory myofibroblastic sarcoma:a case report and review of the literature[J].Orv Hetil,2006,147(4):147-158.
[29] Haveman J,Bergs JW,Franken NA,et al.Effect of hyperthermia on uptake and cytotoxicity of cisplatin in cultured murine mammary carcinoma cells[J].Oncol Rep,2005,14(2):561-567.
[30] Franckena M,De Wit R,Ansink AC,et al.Weekly systemic cisplatin plus locoregional hyperthermia:an effective treatment for patients with recurrent cervical carcinoma in a previously irradiated area[J].Int J Hyperthermia,2007,23(5):443-450.
[31]李红.子宫颈癌新辅助化疗的研究进展.辽宁大医药大学学报, 2008,11(10):12-13.
[2] Rose PG.Locally advanced cervical cancer.Curr Opin Obstet Gynecol,2001,(l):65-70.
[3] Scarabelli C,Zarrelli A,Gallo A,et al.Multimodal treatment with neoadjuvant intra-arterial chemotherapy and radical surgery in Patients with IIIb-IVa cervical cancer.A Preliminary study,Cancer,1995,(76):1019-1026.
[4] Park SY, Kim JH, Lee JH. Phase I-II study of neoadjuvant intra-arterial chemotherapy with mitomycin-C,vincristine and cisplatine in patients with stage IIb bulky cercical carcinoma.Cancer,1995,(76):814-823.
[5] Leone B,Vallejo C, Perez J,et al.Ifosfamide and cisplatine as neoadjuvant themotherapy for advanced cervical carcinoma. Am J Clin Oncol,1996,(19):132-135.
[6]赖日权,张小庄.宫颈/阴道组织与细胞病理学诊断.第1版,北京科学出版社,2004,3-5.
[7]周际昌.实用肿瘤内科学.北京人民卫生出版社,1999,33-342.
[8]王玲.宫颈癌病因学研究新近展.中国妇产科临床杂志,2003,4:243.
[9]李庭芳,古丽娜.库尔班,王涛,等.新疆伽师县夏普桃勒乡妇女子宫颈癌防治的研究.新疆医学院学报,1996,19(3)199-203.
[10]拉莱.苏祖克,古丽娜.库尔班,Amy E.Noeffsrniger,等.维吾尔妇女子宫颈癌中p53基因的表达和HPvDNA检测研究.新疆医学院学报,1997,20(2):77-81.
[11]马正海,钱东,马纪,等.中国新疆维吾尔族妇女宫颈癌组织中乳头状瘤病毒16型E6基因的克隆和序列分析生物化学与生物物理进展,2001,28(3):400-404.
[12]古扎丽努尔.阿不力孜,彭芝兰,刘姗玲,等.新疆和田地区维吾尔族妇女宫颈癌组织中HPvDNA的测定[JJ].四川肿瘤防治,2001,14(2):77-81.
[13]古丽娜.库尔班,阿依努尔.买买提,古扎丽努尔.阿不力孜,等.人类乳头瘤病毒及其亚型在新疆南部地区维族妇女宫颈癌组织中的分布.肿瘤,2002,14(2)405-408.
[14]刘萍,陈春林,梁立治,等.介入性化疗在宫颈癌手术前的应用.中国实用妇科与产科杂志,2001,17(11):666-668.
[15]章华文,吴令英.关于子宫颈癌综合治疗的商榷.中华肿瘤志,2003,25:206-208.
[16] Benedetti-Panici P,Greggi S,Colombo A,et al.Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer results from the Italian multicenter randomized study[J].J Clin Oncol,2002,20(1):179-188.
[17] Maneo A,Colombo A,Landoni F,et al.Treatment of stage IIIB cervical carcinoma a comparison between radiotherapy,concur-rent chemo-radiotherapy and neoadjuvant chemotherapy[J].Mi-nerva G inecol,2005, 57(2):141-152.
[18] Fattorossi A,Battaglia A,Ferrandina G,et al.Neoadjuvant therapy changes the lymphocyte composition of tumor-draining lymph nodes in cervical carcinoma[J].Cancer,2004,100(7):1418.
[19] Antonella Savarese,Franeeseo Cognetti.New drugs in the treatment of recurrent or metastatic cervical cancer. Critical Reviews on Oncology / hematology ,2003,48(30):323-327.
[20] Kobayashi K,Furukawa A,Takahashi M,et al.Neoadjuvant intra-Arterial chemotherapy for locally advanced uterine cervical cancer: Clinical efficacy and Factors Influencing response. Cardiovasc Intervent Radiol,2003,26(2):20-25.
[21]贺青蓉.介入治疗30例中、晚期宫颈癌疗效观察.临床放射学杂志,2002,18(11): 995-996.
[22] Park DC,Kim JH,Lew YO,Kim DH,et tl.Phase II trial of neoadjuvant paclitaxel and cisplatin in uterine cervical cancer[J].Gynecol oncol.2004 ,92(1):59-63.
[23] Mutch DG,Bloss JD.Gemeitabine in cervical cancer[J].Gynecol Oneol,2003,90(2):8-15.
[24] Va11ejo CT,Machiavelli MR,Perez JE,RomeroAO,et al.Docetaxel as neoadjuvant chemotherapy in Patients with advaneed cervical eareinoma[J].Am J Clin oncol.2003,26(5):477-482.
[25]陈春林,刘佩鸣,孙明晖,等.不同途径盆腔动脉灌注化疗组织血浆中铂浓度的研究.中国实用妇科与产科杂志, 1998, 14:357-358.
[26] Stewand PSL, Stenven MA. Clinical pharmacology of intraarterial cisddiam minedich coroplatinum (Ⅱ).Center Reseach,1983,43:97-106.
[27]孙秀丽,王建六,屠铮,等.子宫内膜癌术中区域性动脉灌注化疗的治疗观察.中国妇产科临床杂志, 2003, 4:165-167.
[28] Reuter H.Interventional therapy timing crucial in cervical cancer[J].Eur Cancer,2003,39:2470.
[29] Usuki N,Hitokawa K,Tashiro T,et al. Intra-arterial chemotherapy for uterine cervical adenoarcinoma evaluation of its efficacy as therapy. Nippo Jgaku Hoshasen Gakkai Zasshi,1999,59(12):670-673.
[30] Nagata Y,Araki N,Kimura H,et al.Neoadjuvant chemotherapy by transcatheter arterial infusion method for uterine cervical cancer.J Uasc Interv Radiol,2000,11(3):313.
[31] Brader KR,Motris M,Levenbaek C,et al.Chemotherapy for cervical carcinoma:factors determining response and implications for clinical trial desigin. J Clin oncol,1998,6(5):1879-1884.
[32] Kobeyashi K,Furukawa A,Takahashi M,et al.Neoadjuvant intra-arterial chemotherapy for locally advanced uterine cervical cancer:Clinical efficacy and factors influencing response. Cardiovase Intervent Radiol,2003,26(2):20-25.
[33] Fujiwaki R,Maede Y,Ohnishi Y,et al.Prognosis of patienis with stage IIIb-IVa squamous cell carcinoma of the cervix following intra-artirial neoadjuvant chemotherapy. J ExP Clin Cancer Res,1999,18(2):143-146.
[34] Minagaway Y,Kigawa J,Irie T,e tal.Radical surgery following neoadjuvant chemotherapy for patients with stage IIIb cervical cancer.Ann Surg Oncol,1998,5(6):539-543.
[35] Benedetti-Paniei P,Greggi S,Colombo A,et al.Neoadjuvant chemotheraphy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer:results from the Ita1ian mu1tieenter randomized study.J Clin Oncol,2002,20(1):179-183.
[36]吕雯,麻亚茜,隋丽华.新辅助化疗对宫颈微血管密度及血管内皮生长因子的影响.现代妇产科进展,2004,13:28-30.
[37] Kobayashi K,Furukawa A,Takahashi M,et al.Neoadjuvant intra-arterial chemotherapy for locally advanced uterine cervical cancer: clinical efficacy and factors influencing response,Cardiovasc Intervent Radiol,2003,26(3):234-241.
[38] Vagno G,Cormio G,Pignata S,et al.Cisplatin and vinorelbine as neoadjuvant chemotherapy in locally advanced cervical cancer:aphase II study.Int J Gynecol Cancer,2003,13(3):308-312.
[39] Yamakawa Y,Fujimura M,Hidaka T,et al.Neoadjuvant intrarterial infusion chemotherapy in patients with stage IB2-IIIB cervical cancer.Gynecol Oncol,2000,77(2):264-270.
[40] Nagata Y,Araki N,Kimura H,et al.Neoadjuvant chemotherapy by transeatheter terial infusion method for uterine cervical cancer:J Vase Int Radiol,2000,11(3):313-319.
[41] Lopez-Graniel C,Reys M,Chanona G,et al.Type III radical hysterectomy after Induction chemotherapy for patients with locally advanced cervical carcinoma[J].Int J Gynecol cancer,2001,1(3):210-217.
[42] Sardi JE,Boixadera MA,Sardi JJ.Neoadjuvant chemotherapy in cervical cancer:a new trend.Curr Opin Obstet Gynecol,2005,17(1):43-47.
[43] Panetta A,Angelelli B,Martoni A.Pilot study on induction chemotherapy with cisplatin,epirubicin,etoposide and bleomycin in cervieal stage Ib,IIa and IIb.Anti cancer Res,1999,19(IB):765-768.
[44]吕雯,麻亚茜,隋丽华.新辅助化疗对宫颈微血管密度及血管内皮生长因子的影响.现代妇产科进展,2004,13:28-30.
[45] Fujiki R,Iida K,Ohnishi Y,et al.Intra-arterial neoadjuvant chemotherapy followed by radical surgery and radio therapy for stage IIb cervical carcinoma.Anti cancer Res,1997,17(SB):3751-3755.
[46] Seambja G,Ferrandina G,Distefano M,etal.Is there a place for a less extensive radical surgery in locally advanced cervical cancer patients Gynecol Oncol,2001,83:319-324.
[47]常丽锦.子宫颈癌的新辅助治疗.现代妇产科进展,2003,12(2):135.
[48]丁丽珠,李诚信.Ib-Hb期宫颈癌术前辅助化疗、放疗的疗效分析[J].中国癌症杂志,2004,14(6):558-562.
[49]段萍,孙敏.术前化放疗治疗11期宫颈癌疗效观察[J].浙江肿瘤,2000,6(4):208-210.
[50] Nagata Y, Okajima K, Konishil, et al. Clinical results of trans-catheterarterial infusion for uterine cervical cancer. Am J C1in Oncol,1999,22(1):97-102.
[51] Sugiyama T, Nishide T, Hasuo Y, et al. Neoadjuvant intra-arterial chemotherapy Followed by radical hysterectomy and/or radiotherapy for locally advanced cervical cancer. Gynecol Oncol,1998,69(2):130-136.
[52] Minagawa Y, kgawa J, Irie T, et al.Radical surgery following neoadjuvant chemotherapy for patienis with stage IIIB cervical cancer. Ann Surg Oncol,1998,5(6):539-543.
[53]陈春林,谭道彩,梁立治,等.动静脉灌注化疗子宫颈癌组织药物浓度的比较.中华妇产科杂志,1995,30(5):298.
[54] Adachi S, OAdachi S, Ogasawara T,et al. Intravenous nedaplatin and intraarterial cisplatin with transcatheter arterial embolization for patients with locally advanced uterine cervical cancer.Int J Clin Pharmacol Res,2001,21(3-4):105-106.
[55] Itamochi H, Kigawa J, Minagawa Y, et al. Antitum or effects of internal iliac arterial infusion of platinum compounds in a rabbit cervical cancer model,Obstet gynecol,1997,89:286.
[56]贾丽辰,王昭梅,黄淑馨,等.介入放射学在妇科恶性肿瘤中的应用.上海医学,1991,11(11):675.
[57] YamakawaY,FujimuraM,Hidaka T,et al.Neoadjuvantintraaterial infusion chemotherapy in patients with stage IB2-IIIBcervical cancer.GynecoOncol,2000,77(4):264-270.
[58] Onishi H,Yamaguchi M,Kuriyama K,et al.Effect of concurrent intraarterial infusion of platinum drugs for patients with stage III or IV uterine cervical cancer treated with radical radiation therapy.[J].Cancer J Sci Am,2000,6(1):40-45.
[59] Yamakawa Y, Fujimura M, Hidaka T,et al.Neoadjuvant in-traavterial infusion chemotherapy in patients with stage Ib2-IIIb cervix cancer[J].Gynecologic Oncology,2000,77:264-270.
[1]龚沂,蔡丽萍.宫颈癌的新辅助化疗.江西医学院学报,2004,44(5):43-44.
[2] Sardi J E,Boixadera M A,Sardi J J.Neoadjuvant chemotherapy incervical cancer:a new trend[J].Curr Opin Obstet Gynecol,2005,17(1):43-47.
[3]赵文娟.新辅助化疗在宫颈癌术前治疗中的应用[J]职业与健康,2007,23(9): 761-762.
[4]马秋英.宫颈癌手术前治疗[J].华夏医学,2007,20(5):1145-1148.
[5]王绍光.妇科恶性肿瘤动脉化疗的种类、途径和方式,实用妇产科杂志,2006,8[22]55-60.
[6] Kobayashi M,Yamamoto H, SugimotoT,et al.Intraoperative local infu-sion chemotherapy (ILIC) For gastric cancer.Gan-To-Kagaku-Ryo-ho,1998,25:1281- 1286.
[7]陈春林,刘佩鸣,孙明晖,等.不同途径盆腔动脉灌注化疗组织血浆中铂浓度的研究,中国实用妇科与产科杂志,1998,14:357-358.
[8] Stewand PSL,Stenven MA.Clinical pharmacology of intraarterial cisddi-am minedich coroplatinum (II) Center Reseach,1983,43:97-106.
[9]孙秀丽,王建六,屠铮,等.子宫内膜癌术中区域性动脉灌注化疗的治疗观察.中国妇产科临床杂志,2003,4:165-167.
[10]张国楠,宋水勤.宫颈癌动脉化疗进展.实用妇产科杂志,2006,8(22)70-72.
[11] Tabata T,Takeshima N,NishidaH,et al.Arandomized study ofprimary bleomycin, vincristine,mitomycinandcisplat(BOMP)chemotherapy followed by radiotherapy versus radiotherapy alone instage IIIB and IVA squamous cell carcinoma of the cervix[J].An-ticancer Res,2003,23:2885-2890.
[12]翟建军,战媛,闻静,等.局部晚期子宫颈癌应用新辅助化疗的探讨[J].中国医刊,2007,42(10):56-58.
[13] Adachi S,Ogasawara T,Tsubamoto H,et al.Intravenous nedapl-atin and intraarterial cisplatin with transcatheter arterial emboliza-tion for patientswith locally advanced uterine cervical cancer[J].Int JClin PharmacolRes,2001,21(3~4):105-110.
[14] Abu-Surrah AS,Kettunen M.Platinum group antitumor chemistry:design and development of newanticancer drugs complementary to cisplatin[J].Curr Med Chem,2006,13(11):1337-1357.
[15]于海林,鹿欣.铂类抗癌药物在妇科肿瘤治疗中的应用.世界临床药物医药专论,world clinical drugs, 2008[29]:7.
[16]刘飞,郭美君,苏日娜.宫颈癌的同步放化疗与新辅助化疗的研究进展.A cta A cadMed Nei Mongol, 2006,12:28.
[17]苗华芹,周登光,周登峰.高危宫颈癌化疗进展,实用癌症杂志,2005,5(20)3-5.
[18]刘颖,熊正爱.宫颈癌化学药物治疗进展.重庆医学学报,第2008,6(37)12-14.
[19] Serur E,Mathews RP,Gates J,et al.Neoadjuvant chemotherapy in stage IB2 squamous cell carcinoma of the cervix[J]Gynecol Oncol,1997,65(2):348.
[20] Neoadjuvant Chemotherapy for Cervical Cancer Meta-analysis Collaboration(NACCCMA)Collaboration Neoad-juvant chemotherapy for locally advanced cervix cancer[M/CD].Cochrane Database Syst Rev,2004,(2): 1774.
[21] Minagawa Y,Kigawa J,Irie T,et al.radical surgery following neoadjuvant chemotherapy for patients with stageIIIB cervical cancer[J].Ann Surg Oncol,1998,5(6):539.
[22] Chauvergne J,Lhomme C,Rohart J et al.Neoadjuvant chemoth-erapy of stage IIb or IIIcancers of the uterine cervix.Long-termresults of a multicenter randomized trial of 151 patients[J].Bull Cancer,1993,80(12):1069.
[23] Seoud M,Geara FB,Shamseddine A,et al.Short duration neoad-juvant chemotherapy followed by radiotherapy for advanced car-cinoma of the cervix:results and prognostic variables[J].Eur J Gynaecol Oncol,2003,24(2):163.
[24] Yamakawa Y,Fujimura M,Hidaka T,et al.Neoadjuvant intraar-terial infusion chemotherapy in patients with stageⅠB2~ⅢB cervical cancer[J].Gynecol Oncol,2000,77(2):264.
[25] Focan C,Denis B,Kreutz F,et al.Ambulatory chronotherwith 5-fluo-rouracil,folinic acid,and carboplatin for advanced non-small cell lung cancer.A phase II feasibility trial[J].J Infus Chemother,1995,5(3suppl):148~152.
[26]宋红林,宫颈癌的新辅助时辰化疗,Modern oncology,2003,8(11)3 186.
[27] CW,Park HJ,Lee CK,et al.Implications of increased tumor blood flow and oxygenation caused by mild temperature hyperther-mia in tumor treatment[J].Int J Hyperthermia,2005,21(8):761-770.
[28] Matrai Z,Peley G,Kovacs T,et al.Cytoreductive surgery and in-traperitoneal hyperthermic chemoperfusion for peritoneal carcino-matosis caused by recurrent inflammatory myofibroblastic sarcoma:a case report and review of the literature[J].Orv Hetil,2006,147(4):147-158.
[29] Haveman J,Bergs JW,Franken NA,et al.Effect of hyperthermia on uptake and cytotoxicity of cisplatin in cultured murine mammary carcinoma cells[J].Oncol Rep,2005,14(2):561-567.
[30] Franckena M,De Wit R,Ansink AC,et al.Weekly systemic cisplatin plus locoregional hyperthermia:an effective treatment for patients with recurrent cervical carcinoma in a previously irradiated area[J].Int J Hyperthermia,2007,23(5):443-450.
[31]李红.子宫颈癌新辅助化疗的研究进展.辽宁大医药大学学报, 2008,11(10):12-13.